EUVIMEDObjevte EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC 4.0

Belatacept and regulatory T cells in transplantation: synergistic strategies for immune tolerance and graft survival

Gil-Ran Kim iD, Kyung-Ho Nam iD, Je-Min Choi iD

Clinical Transplantation and Research · 2024-12-31 · 38 (4) · 326-340

DOI: 10.4285/ctr.24.0057 ↗

At a glance

Übersichtsarbeit in Clinical Transplantation and Research, published online on 2024-12-18. Written by Gil-Ran Kim and 2 co-authors. Institution: Department of Life Science, College of Natural Sciences, Hanyang University, Seoul, Korea. Cited 5 times so far (Crossref); 87 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: National Research Foundation of Korea.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Calcineurin inhibitors (CNIs) have been a cornerstone in solid organ transplantation for many years; however, their prolonged use is linked to significant adverse effects, most notably nephrotoxicity. Belatacept, a modified version of cytotoxic T lymphocyte antigen-4 immunoglobulin with increased binding affinity for its ligand, has emerged as a viable alternative to traditional CNIs due to its lower toxicity profile. Despite these benefits, belatacept is associated with a higher rate of acute rejection, which presents a challenge for long-term graft survival. This review reevaluates the limitations of belatacept in achieving long-term acceptance of transplants and highlights the importance of regulatory T (Treg) cells in maintaining immune tolerance and preventing graft rejection. Additionally, it discusses the potential benefits of combining therapies that boost Treg cells with belatacept to increase the effectiveness of immunosuppression and improve graft outcomes.

Subjects

Author keywords

AbataceptRegulatory T cellsTransplantation

Authors and institutions

  • Department of Life Science, College of Natural Sciences, Hanyang University, Seoul, Korea.
  • Research Institute for Natural Sciences, Hanyang University, Seoul, Korea.
  • Hanyang Institute of Bioscience and Biotechnology, Hanyang University, Seoul, Korea.
  • Research Institute for Convergence of Basic Sciences, Hanyang University, Seoul, Korea.

ORCID profiles: Gil-Ran Kim, Kyung-Ho Nam, Je-Min Choi

Funding

  • National Research Foundation of Korea

Cite

APA

Kim, G. R., Nam, K. H., & Choi, J. M. (2024). Belatacept and regulatory T cells in transplantation: synergistic strategies for immune tolerance and graft survival. Clinical Transplantation and Research, 38(4), 326-340. https://doi.org/10.4285/ctr.24.0057

Vancouver

Kim GR, Nam KH, Choi JM. Belatacept and regulatory T cells in transplantation: synergistic strategies for immune tolerance and graft survival. Clinical Transplantation and Research. 2024;38(4):326-340. doi:10.4285/ctr.24.0057

BibTeX
@article{Kim2024,
  author = {Kim, Gil-Ran and Nam, Kyung-Ho and Choi, Je-Min},
  title = {Belatacept and regulatory T cells in transplantation: synergistic strategies for immune tolerance and graft survival},
  journal = {Clinical Transplantation and Research},
  year = {2024},
  volume = {38},
  number = {4},
  pages = {326--340},
  doi = {10.4285/ctr.24.0057}
}
Start for free →